Cartesian Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cartesian Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2024.
  • Cartesian Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $13.8M.
  • Cartesian Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$230M, a 555% decline year-over-year.
  • Cartesian Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$220M, a 721% decline from 2022.
  • Cartesian Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $35.4M.
  • Cartesian Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$25.7M, a 62.7% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$230M $13.8M +$25.2M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$255M -$56.8M -$35.2M -162% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-08
Q4 2023 -$220M -$178M -$184M -3115% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$36.2M -$9M -$1.11M -14.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$35.1M -$11.4M -$20M -232% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$15.1M -$21.7M -$50.4M -175% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-08
Q4 2022 $35.4M $5.89M -$6.35M -51.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $41.7M -$7.89M +$10M +55.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $31.7M $8.6M +$4.04M +88.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 $27.7M $28.8M +$53.4M Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$25.7M $12.2M +$27.7M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-07
Q3 2021 -$53.4M -$17.9M -$8.17M -83.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$45.2M $4.57M +$28.6M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$73.9M -$24.6M -$4.98M -25.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$68.9M -$15.4M -$558K -3.75% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 -$68.3M -$9.73M +$2.27M +18.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$70.6M -$24.1M -$7.69M -46.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$62.9M -$19.6M -$7.55M -62.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$55.4M -$14.9M -$237K -1.62% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$55.1M -$12M +$4.01M +25% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$59.1M -$16.4M +$2.4M +12.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$61.5M -$12.1M +$3.81M +24% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$65.3M -$14.7M +$4.89M +25% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$70.2M -$16M -$1.33M -9.03% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$68.9M -$18.8M -$2.83M -17.7% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$66.1M -$15.9M -$754K -4.98% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$65.3M -$19.5M -$5.46M -38.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-15
Q3 2017 -$59.9M -$14.7M -$6.95M -89.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-15
Q2 2017 -$52.9M -$16M -$9.04M -131% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-15
Q1 2017 -$43.9M -$15.1M -$7.66M -102% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-15
Q4 2016 -$36.2M -$14.1M -$7.23M -106% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$29M -$7.73M -$2M -35% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$27M -$6.92M -$56K -0.82% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$26.9M -$7.48M -$1.74M -30.4% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$25.2M -$6.85M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-28
Q3 2015 -$5.73M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-28
Q2 2015 -$6.87M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-28
Q1 2015 -$5.73M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.